Bayer Backs Vesigen To Improve Cell and Gene Therapy Delivery

New Biotech Approach For Gene Editing, mRNA

Serial entrepreneur Robert Millman is leading the new biotech which thinks it has the answer to getting CRISPR and RNA-based therapies into cells more efficiently

Kendall_Square — Vesigen has its headquarters in Kendall Square, the heart of Boston's biotech world.

A new biotech start-up has been spun out of Harvard University with the goal of finding a better way of delivering novel therapeutics such as CRISPR-cas9, RNA molecules and other large proteins to targets inside the cell.

Vesigen Therapeutics builds on the work of Quan Lu, professor of environmental genetics and physiology at the Harvard Chan School, and has been launched with a $28.5m series A financing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

16 May 2025

• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

15 May 2025

• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

15 May 2025

• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.